An EU biotech looks to rewrite the ugly history of phosphatases, and it’s taking $24M in funding to get off the ground

Long a lame duck in drug development, phosphatase enzymes are gaining some renewed interest after the success of a suite of Big Pharmas in hitting targets previously thought undruggable. Now, an EU biotech with some serious scientific backers is looking to bust the doors on phosphatases wide open.

Leaning on…